ARQT

9.425

1.94% 0.165

Dopo l'orario di chiusura: 9.45 0.025 +0.27%

Arcutis Biotherapeutics Inc (ARQT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARQT Giù? Forum Previsione

Precedente Chiudi:

$9.26

Aprire:

$9.27

Volume 24 ore:

1.46M

Relative Volume:

0.74

Capitalizzazione di mercato:

$1.09B

Reddito:

$59.61M

Utile/perdita netta:

$-262.14M

Rapporto P/E:

-1.7013

EPS:

-5.54

Flusso di cassa netto:

$-247.49M

1 W Prestazione:

-12.92%

1M Prestazione:

+8.26%

6M Prestazione:

+2.61%

1 anno Prestazione:

+362.74%

Intervallo 1D:

$8.90

$9.46

Intervallo di 1 settimana:

$8.90

$10.76

Portata 52W:

$1.76

$13.17

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Nome

Arcutis Biotherapeutics Inc

Settore

Healthcare (1205)

Industria

Biotechnology (682)

Telefono

805-418-5006

Indirizzo

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Dipendente

296

Cinguettio

@ArcutisBio

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

ARQT's Discussions on Twitter

Confronta ARQT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARQT	9.42	1.09B	59.61M	-262.14M	-247.49M	-5.54
VRTX	467.12	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	762.38	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	567.35	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.83	24.08B	3.30B	-501.07M	1.03B	11.54

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-03	Aggiornamento	Mizuho	Neutral → Buy
2023-10-26	Downgrade	Mizuho	Buy → Neutral
2023-10-13	Downgrade	Goldman	Buy → Neutral
2022-09-07	Iniziato	Needham	Buy
2022-03-17	Iniziato	Goldman	Buy
2021-06-30	Iniziato	Mizuho	Buy
2021-05-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Aggiornamento	Goldman	Neutral → Buy
2020-10-08	Iniziato	Truist	Buy
2020-02-25	Iniziato	Cantor Fitzgerald	Overweight
2020-02-25	Iniziato	Cowen	Outperform
2020-02-25	Iniziato	Goldman	Neutral
2020-02-25	Iniziato	Guggenheim	Buy

Mostra tutto

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

10:29 AM

Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha

10:29 AM

Nov 16, 2024

Long Term Trading Analysis for (ARQT) - Stock Traders Daily

Nov 16, 2024

Nov 15, 2024

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha

Nov 15, 2024

Nov 14, 2024

Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com

Nov 13, 2024

Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com

Nov 13, 2024

Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times

Nov 13, 2024

Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR

Nov 11, 2024

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - Yahoo Finance

Nov 11, 2024

Nov 08, 2024

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024

Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com

Nov 07, 2024

Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024